Potential Conflict of Interest Disclosures

Dr Abreo has been a participant in advisory boards with Horizon Therapeutics and Regeneron Pharmaceuticals.Dr Anvari has received research funding from NIH/NIAID, Regeneron, AstraZeneca, and DBV Technologies. She has received consultancy fees from DBV. She serves on the medical advisory board for the International Food Protein-Induced Enterocolitis Syndrome (FPIES) Association.Dr Aquino is the past chair of the Allergic Skin Diseases Committee for American Academy of Allergy, Asthma and Immunology (AAAAI) and a member of the AAAAI Adverse Reactions to Drugs, Biologicals & Latex Committee and Anaphylaxis Committee. She is chair of the 2025 ACAAI Woman in Allergy Award Committee for American College of Allergy, Asthma and Immunology (ACAAI) and a member of the ACAAI Dermatological Allergy Committee Member, Drug Allergy Committee, and Program Directors Committee. She is an associate member of the International Eczema Council.Dr Bingemann has been a speaker for Sanofi and is a consultant for Pharming, Sanofi, and Regeneron.Dr Bird is chair and a previous executive committee member of the American Academy of Pediatrics, Section of Allergy and Immunology. His institution has received payment for contracted research from Abbott, ALK, DBV Technologies, Food Allergy Research and Education (FARE), Genentech, NIH/NIAID, Novartis, Regeneron, and Siolta Therapeutics. He has served as a consultant for Allakos, DBV Technologies, Food Allergy Research & Education (FARE), Genentech, Hanimmune Therapeutics, Infinant Health, and Parexel. He has been a non-CME symposium speaker for DBV Technologies. He serves in noncompensated roles as a medical advisory board member for the International FPIES Association, as an uncompensated independent study monitor for Vedanta, and as past chair of the Stock Epinephrine Advisory Committee for the Texas Department of State Health Services.Dr Brown-Whitehorn has been an investigator in research studies with DBV Technologies, ALK, FARE, Regeneron, and NIH.Dr Chambliss has been a consultant with Novartis and is a current board member for the Texas Allergy Asthma and Immunology Society (TAAIS).Dr Chipps is an advisor for, received consultancy fees from, and is on the speakers’ bureau for AstraZeneca, Regeneron, and Sanofi Genzyme.Dr Chow receives grant support from the National Institutes of Health (grant U01 AI184071). He reports personal fees from Sarepta Therapeutics outside the submitted work.Dr Davis holds stocks in Pfizer, Johnson and Johnson, Abbott, Kenvue, and AbbVie.Dr M Gupta reports receiving grant support from the American Academy of Allergy Asthma and Immunology. She is on the medical advisory board of the International FPIES Association and Alerje, Inc. She is on the board of directors of the International FPIES Association.Dr R Gupta receives research support from the National Institutes of Health (NIH), Food Allergy Research & Education (FARE), Sunshine Charitable Foundation, Genentech, Novartis, and Abbott Laboratories. She serves as a medical consultant/advisor for Food Allergy Research & Education (FARE), Genentech, Novartis, OWYN, Kaléo, Bryn Pharma, Kenvue, ARS Pharmaceuticals, Oracle Life Sciences, and Alpina Biotechnology. Dr Gupta has ownership interest in Yobee Care, Inc. She is currently employed by Ann & Robert H. Lurie Children’s Hospital of Chicago and is a professor of pediatrics & medicine at Northwestern University Feinberg School of Medicine.Dr Hernandez-Trujillo is a grant recipient from the Immune Deficiency Foundation. She has served as a consultant for Pharming. She has received honoraria for speaking for the American College of Allergy, Asthma and Immunology (ACAAI), Food Allergy Research & Education (FARE), Allergy & Asthma Network, and Enzyvant/Sumitomo (SMPA). She has participated in advisory boards for Kaléo, CSL, Takeda, Bayer, Aimmune, Stallergenes Greer, Enzyvant/Sumitomo (SMPA), Pfizer, Sanofi/Regeneron, ARS, Bryn, Novartis, and Genentech. She has served as a speaker for Kaléo, Takeda, CSL, and Genentech. She is chair of the Practice Management Committee for American Academy of Allergy, Asthma and Immunology (AAAAI). She is part of the Immune Deficiency Foundation Medical Advisory Council. She has received royalties from UpToDate. She serves as an assistant editor for Allergy Watch for the ACAAI.Dr Hogan has participated on a speakers’ bureau for ARS.Dr Jefferson reports funding from the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL174407. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Dr Leo participates as part of the National Eczema Association’s Seal Advisory Board.Dr Lester reports organizational work with AAP, American Board of Allergy and Immunology (ABAI), American College of Allergy, Asthma and Immunology (ACAAI), and NESA.Dr Pistiner has served as a consultant/ advisor for AAFA, FARE, AAN, Kaléo, DBV Technologies, Novartis, Bryn, Aimmune, Anjo, and FoodGraph. He has received grants to his institution from Kaléo, the National Peanut Board, Egg Nutrition Center, Kenvue, DBV, AAFA, AAN, ARS, Aquestive, and Stallergenes Greer. He is cofounder of AllergyHome and Allergy Certified Training.Dr Shaker serves as part of the Joint Task Force, American College of Allergy, Asthma and Immunology (ACAAI), and American Academy of Allergy, Asthma and Immunology (AAAAI).Dr Sicherer reports royalty payments from UpToDate and from Johns Hopkins University Press; grants to his institution from the National Institute of Allergy and Infectious Diseases, from Food Allergy Research and Education, from Pfizer, and from Regeneron; and personal fees from the American Academy of Allergy, Asthma and Immunology as deputy editor of the Journal of Allergy and Clinical Immunology: In Practice, outside of the submitted work.Dr Simons is a recipient of funding from the Canadian Institutes of Health Research and CHILD Cohost Study Manitoba Site PI and Executive Member.Dr Stukus has been a consultant for ARS Pharmaceuticals, Aquestive, and Genentech. He has participated in an advisory board for Aquestive. He has received research support from DBV Technologies. He serves as associate editor of Annals of Allergy, Asthma and Immunology. He is vice president for the American College of Allergy, Asthma and Immunology (ACAAI). He is a member of the Executive Committee, Section on Allergy/Immunology, for the American Academy of Pediatrics.Dr Wall has participated in clinical trials with Takeda and Chiesi. He has attended an advisory board for Chiesi.Dr Wang has received research support from the National Institute of Allergy and Infectious Diseases, DBV Technologies, and Siolta.Dr K Williams has been an advisory board member and speaker for Amgen. She has been a consultant and steering committee member for Pharming. Her institution was paid for a principal investigator role in research by GlaxoSmithKline (GSK). She was a recipient of a research grant and was principal investigator of a clinical trial for AstraZeneca. She was the principal investigator for a clinical trial paid to her institution by Cogent Biosciences.The remainder of the authors have no disclosures.